Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

McKESSON/VALU-RITE DEAL CREATES 25,000-PHARMACY MANAGED CARE NETWORK that will cover 4 mil. lives, McKesson announced Dec. 9. The wholesaler maintained that creation of its 25,000-outlet PCS Health System network incorporating the 4,500 independent pharmacies affiliated under the Valu-Rite banner forms "the nation's largest single-provider managed care pharmacy network." Calling Valu-Rite "the nation's largest and fastest growing voluntary organization of independently owned retail pharmacies," McKesson said the agreement gives the affiliated providers "access to the growing number of prescriptions being channeled to pharmacy networks by managed health care organizations." Valu-Rite stores "far outnumber" the largest pharmacy chain in outlets and, if their sales volume were consolidated, would rank as the third- largest chain. The Valu-Rite network offers a "rebate plan on both branded and generic products." Valu-Rite stores can receive rebates of 5% off the acquisition cost of generics in McKesson's program and 1% off brandname drugs purchased from McKesson and "dispensed to certain customers under the now network plans." McKesson said the agreement will give Valu-Rite pharmacies opportunities to increase their business with beneficiaries required to patronize network providers. The Valu-Rite network has grown from less than 4,000 pharmacies since the autumn, when McKesson sales personnel began notifying pharmacies of the wholesaler's plans for Valu-Rite.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts